Nuvilex, Inc. (OTCQB: NVLX) announces it has completed the acquisition of pancreatic cancer treatment technology from a world leader in living-cell encapsulation technology. The technology involves the targeted delivery of encapsulated living cells that are capable of delivering and converting standard inactive chemotherapeutic cancer drugs (pro-drugs) into active, chemotherapeutic (cancer-fighting) drugs directly to the pancreatic tumor. In addition, this technology allows for the use of overall lower pro-drug doses, dramatically decreasing the overall body exposure to such toxic agents, yet with greater clinical effect. This positive clinical effect is due to the mechanism of delivery of the final active cancer-fighting drug, namely the encapsulated pro-drug-converting living cells specifically delivered to the pancreatic tumor site.
